ECT vs Ketamine for Depression: What the Evidence Says (2026)

This is the comparison at the sharp end of depression care. Electroconvulsive therapy (ECT) is the treatment European guidelines reserve for the severest cases; ketamine is the newer arrival often described — sometimes by people selling it — as the modern replacement. The evidence says something more precise and more interesting than either camp's version. This page lays out what the trials and meta-analyses actually found, where each treatment's real advantages sit, and why the answer differs depending on which patients you ask about. For the wider map of options when treatment has not worked, start with our overview; ketamine's own evidence gets a full review in the ketamine evidence review.

TL;DR In severe depression, ECT is still the better-supported treatment: the 2022 JAMA Psychiatry meta-analysis found it outperformed ketamine, and a 2026 time-course meta-analysis found it worked faster, with a projected moderate advantage by the end of a four-week course. In nonpsychotic treatment-resistant depression — a deliberately narrower group — the large ELEKT-D trial found ketamine non-inferior. Ketamine is gentler on memory and cognition and needs no general anaesthesia; ECT remains the reference where psychotic features, catatonia or life-threatening severity are in play. Both are specialist hospital-level decisions. Neither is bookable off a menu, and this page is not a substitute for the psychiatric consultation that decision requires.

Two treatments, two orders of intervention

ECT is a hospital treatment under general anaesthesia that guidelines reserve for severe depression — when a rapid response is needed or when other treatments have failed (NICE NG222). A brief electrical stimulus induces a controlled seizure under anaesthesia and muscle relaxation; a course typically involves several sessions per week over a few weeks. It carries decades of clinical use, close regulation, and side effects (particularly around memory) that the treating team is obliged to discuss with you. It is nobody's first step, and for the severest depression it remains one of the most effective treatments medicine has.

Ketamine is a dissociative anaesthetic used off-label for depression, typically as intravenous infusions in a clinic under monitoring. Racemic ketamine, given by intravenous infusion, produces a rapid antidepressant effect that small controlled trials have shown consistently since 2006; the benefit of a single infusion usually fades within one to two weeks, and repeated infusions are used to extend it, with relapse common after stopping (Zarate et al. 2006; Marcantoni et al. 2020). No general anaesthesia, no induced seizure — but dissociation during the session, a transient rise in blood pressure and heart rate, and, with repeated or long-term use, real risks: bladder and urinary-tract damage (ketamine uropathy), dependence and, less commonly, liver and bile-duct injury.

Fact box — what the comparative evidence found - Severe depression, all comers: ECT superior to ketamine on depression outcomes (Rhee et al., JAMA Psychiatry 2022). - Speed and four-week course: ECT improved symptoms faster, projected moderate advantage by week four (Nikolin et al., Translational Psychiatry 2026). - Nonpsychotic treatment-resistant depression: ketamine non-inferior to ECT (ELEKT-D, Anand et al., NEJM 2023). - Network meta-analysis incl. rTMS (35 RCTs): no significant response/remission differences; ketamine scored higher on acceptability; confidence in the evidence very low (Terao et al. 2025). - Cognition: memory-related side effects are ECT's characteristic burden; ketamine's sits in dissociation and repeated-use risks.

What the evidence says, carefully

Where ECT wins

The broadest synthesis is the 2022 systematic review and meta-analysis in JAMA Psychiatry (Rhee et al.), which pooled the randomised trials comparing ketamine with ECT in major depressive episodes and found ECT superior on depression severity outcomes (Rhee et al. 2022). A 2026 meta-analysis took a different angle — modelling the time course of response across seven studies and 731 participants — and reached a complementary conclusion: ECT produced a faster rate of improvement, amounting to a projected moderate efficacy advantage over ketamine by the end of a four-week course (Nikolin et al. 2026). For hospitalised and severe episodes — the population ECT was built for — the comparative evidence has not dethroned it.

Where ketamine holds its ground

The largest single trial tells the other half of the story. ELEKT-D (Anand et al., NEJM 2023) randomised 403 patients with treatment-resistant major depression — excluding psychotic features — to ketamine infusions or ECT, and ketamine met the non-inferiority criterion (Anand et al. 2023). That exclusion is not a footnote; psychotic depression is precisely where ECT's effect sizes are largest, so the trial asked a fair but narrower question: for outpatient-level, nonpsychotic treatment-resistant depression, is ketamine a defensible alternative? Its answer was yes. The 2025 network meta-analysis adds that across 35 mostly small RCTs, IV ketamine had significantly higher acceptability (fewer patients dropping out for any reason) than ECT, with efficacy differences not significant and evidence confidence rated very low (Terao et al. 2025).

How both can be true

The apparent contradiction dissolves once populations are kept straight. Meta-analyses that include severe, hospitalised and psychotic cases favour ECT; the flagship trial that excluded them found parity. Reviews on both sides flag the same limits — small samples, unblindable treatments, short follow-up. The fair reading in 2026: *ECT remains the reference standard for the severest depression; ketamine is a credible, less invasive alternative for the nonpsychotic treatment-resistant middle ground — and the choice between them is a clinical judgement about your episode, not a league table.*

Side effects: different currencies

ECT's characteristic cost is cognitive. Memory effects — particularly retrograde amnesia around the treatment period — are the side effect the treating team is obliged to discuss, and modern technique (electrode placement, pulse width, dosing) exists largely to reduce them. It also requires repeated general anaesthesia, with everything that entails.

Ketamine is gentler on memory in the trial data — cognitive outcomes in ELEKT-D favoured or matched ECT rather than trailing it — but it is not free. During an infusion, ketamine commonly causes dissociation, a short-lived rise in blood pressure and heart rate, nausea, dizziness and perceptual changes; these resolve as the drug clears, which is why sessions include monitoring and a recovery period. The risks that deserve real attention come with repeated or long-term use — ketamine uropathy, dependence and, less commonly, liver injury — documented mainly in chronic misuse but relevant to any repeated medical use; the full safety picture is in our ketamine evidence review.

Neither treatment is take-home. Both belong in monitored clinical settings, and after either you do not drive yourself home.

Availability in Europe: opposite doors

ECT runs inside public psychiatry. Every European country's hospital system provides it under national mental-health law and guidelines, typically for inpatients or severe cases under specialist care — you reach it through a psychiatric service, not a website.

Ketamine for depression mostly runs outside that system. It is used off-label almost everywhere in Europe, largely in private clinics; public funding for IV ketamine remains uncommon, with Norway's specialist-service decision of August 2025 the clearest exception and France's March 2026 compassionate framework a narrower one. The approved, reimbursable relative is esketamine nasal spray (Spravato) — a different product with its own evidence review and practical comparison. Where private ketamine is the realistic route, our directory lists verified clinics and our cost guide the published prices; the eligibility check sorts out which doors exist in your country.

Frequently asked questions

Is ketamine replacing ECT?

No. Trial activity and clinic growth are on ketamine's side, but the comparative evidence has not displaced ECT for severe depression — the 2022 meta-analysis favoured ECT, and guidelines still reserve it for exactly the severe, urgent cases where it is strongest. What ketamine has done is widen the middle ground: for nonpsychotic treatment-resistant depression, ELEKT-D showed it is a defensible alternative.

Which is safer?

They spend risk in different currencies, so "safer" has no single answer. ECT's burden is cognitive (memory effects) plus repeated general anaesthesia, inside a heavily regulated hospital pathway. Ketamine avoids both but brings dissociation and blood-pressure rises per session and bladder-damage and dependence risks with repeated use. Individual factors — cardiovascular status, psychiatric history, anaesthesia risk — can tip the balance either way, which is one more reason this is a specialist decision.

Can I choose ketamine to avoid ECT's memory effects?

That preference is legitimate and worth voicing — acceptability is precisely where ketamine scored better in the network meta-analysis. But whether it is clinically sensible depends on your episode: with psychotic features, catatonia or life-threatening severity, steering away from ECT can mean steering away from the treatment most likely to work. Put the preference on the table with the psychiatric team rather than deciding alone.

Does anything here apply to esketamine (Spravato)?

Only partly. The head-to-head trials above used racemic IV ketamine, not the nasal spray. Esketamine has its own regulatory trial programme and its own approved indications — including, in a psychiatric emergency, acute short-term use alongside an oral antidepressant. See the esketamine evidence review.

How do I even get assessed for either?

Through psychiatry, with your treatment record in hand. ECT is proposed by a treating psychiatric team, usually at the severe end of an episode. For ketamine, a legitimate clinic will require a psychiatric assessment and screening rather than selling you a course; what that screening should cover is in how to prepare for ketamine therapy. If you are at the two-failed-antidepressants stage and mapping options, start here.

Sources

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. ECT and ketamine decisions are specialist decisions made with a psychiatric team that knows your history. If you are in crisis, contact your local emergency number (112 in the EU) or a crisis line immediately.

ECT vs Ketamine: What the Evidence Says

On this page